Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia

Xingcheng Yang1,2†, Ling Ma3†, Xiaoying Zhang1,2, Liang Huang1,2* and Jia Wei1,2*

Abstract
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately 30% of MDS eventually progress to AML, associated with increasingly aggressive neoplastic hematopoietic clones and poor survival. Dysregulated immune microenvironment has been recognized as a key pathogenic driver of MDS and AML, causing high rate of intramedullary apoptosis in lower-risk MDS to immunosuppression in higher-risk MDS and AML. Immune checkpoint molecules, including programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), play important roles in oncogenesis by maintaining an immunosuppressive tumor microenvironment. Recently, both molecules have been examined in MDS and AML. Abnormal inflammatory signaling, genetic and/or epigenetic alterations, interactions between cells, and treatment of patients all have been involved in dysregulating PD-1/PD-L1 signaling in these two diseases. Furthermore, with the PD-1/PD-L1 pathway activated in immune microenvironment, the milieu of BM shift to immunosuppressive, contributing to a clonal evolution of blasts. Nevertheless, numerous preclinical studies have suggested a potential response of patients to PD-1/PD-L1 blocker. Current clinical trials employing these drugs in MDS and AML have reported mixed clinical responses. In this paper, we focus on the recent preclinical advances of the PD-1/PD-L1 signaling in MDS and AML, and available and ongoing outcomes of PD-1/PD-L1 inhibitor in patients. We also discuss the novel PD-1/PD-L1 blocker-based immunotherapeutic strategies and challenges, including identifying reliable biomarkers, determining settings, and exploring optimal combination therapies.

Keywords: Myelodysplastic syndrome, Acute myeloid leukemia, Programmed cell death-1, Programmed cell death ligand-1, Immune checkpoint, Hypomethylating agent, AML transformation

Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal myeloid neoplasms originating from hematopoietic stem cells (HSCs). MDS has a potential high risk of developing to acute myeloid leukemia (AML), which has been an increasing global burden during the past 28 years [1, 2]. About 30% of MDS cases eventually transform into AML, which is diagnosed by a blast amount of ≥20% of total nucleated cells in BM [3]. Recurrent genetic mutations, epigenetic changes and aberrant immune signaling pathways have been implicated in disease progression, contributing in a multistep and evolutionary way to MDS/AML transformation [4–7]. On one hand, genetic and epigenetic mutations in blasts confer these mutant cells with capabilities of self-renewal and clonal progression [6]. On the other hand, the inflammatory milieu in the BM of patients imposes selective pressure both on mutant clones and on normal hematopoietic...
stem/progenitor cells (HSPCs), further driving the emergence of subclones, which exhibit a competitive advantage in the milieu over normal HSPCs [8, 9]. In addition, recent studies also have shown a connection between epigenetic alterations and dysregulated inflammatory pathways, including EZH2 and KDM6B signalings that play important roles in leukemic transformation, was implicated in the dysregulated innate immune responses observed in MDS/AML patients [10–16]. In general, lower-risk MDS is often linked to increased intramedullary apoptosis and pyroptosis, accompanied by elevated interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), S100A8/S100A9 and NLRP3 inflammasome levels [17–19]. While in higher-risk MDS and AML, the milieu in BM is relatively more immunosuppressive, as effector T cells and NKs are exhausted and functionally impaired, accompanied by elevated frequencies of hyperfunctional regulatory T cells (Tregs) [20–26]. Furthermore, immune checkpoint molecules, including PD-1, cytotoxic T-lymphocyte-associated-protein 4 (CTLA4), T-cell immunoglobulin mucin-3 (TIM-3), T cell immunoglobulin and ITIM domain (TIGIT), lymphocyte activation gene-3 (LAG-3), also have critical functions in this process by protecting blasts from host immune surveillance [27–32]. Mounting evidence has demonstrated the dynamic function of PD-1/PD-L1 signaling in promoting leukemogenesis in MDS/AML, thus increasing attention are drawn to this field.

Physiologically, PD-1 is expressed on activated T cells, Tregs and B cells. PD-1 prevents immune over-activation by binding to its receptor PD-L1/PD-L2 found mainly on macrophages and dendritic cells (DCs) [33–37]. Following binding to PD-L1, the intracellular tyrosine residue of PD-1 is phosphorylated, followed by subsequent SHP-1 and SHP-2 recruitment, which disrupts a series of downstream molecules in TCR signaling, e.g., PI3K/AKT, RAS-ERK1/2 and PKCδ signaling. This in turn promotes effector T cells apoptosis and inhibits proliferation and cytokine secretion of these cells [38–42]. However, this protective function of the PD-1/PD-L1 signaling can also be utilized by tumors to maintain an immunosuppressive tumor microenvironment, favoring cancer cell proliferation [43]. In general, PD-1 binding to PD-L1 favors tumor evasion mainly via the following mechanisms: (1) inhibition of effector T cell function by promoting apoptosis and decreasing proliferation of T cells, and blocking the production of cytokines; (2) downregulation of T-cell receptor (TCR) expression and induction of proliferation in Tregs, which are key mediators suppressing cytokine secretion and proliferation of effector T cells [44–47]; (3) protection of tumor cells by reversely transmitting anti-apoptotic signals through the PD-L1 receptor; (4) formation of a 'molecular shield' to induce resistance against T cell–mediated killing, including Fas- and staurosporine-mediated apoptosis, leukemia-specific cytotoxic T lymphocyte-induced cytolysis and interfered signal transducer and activator of transcription 3 (STAT3)/caspase-7 dependent interferon-mediated cytotoxicity [48, 49]. In addition, reverse signaling mediated by PD-L1 further promotes tumor growth by enhancing glycolytic metabolism in PD-L1+ tumor cells via the Akt/mTOR pathway [50, 51]. In several preclinical studies of AML established in murine models, PD-1/PD-L1 signaling was implicated in leukemia development, e.g., inhibition of host antitumor immune responses, exhaustion of CD8+ T cells and promotion of Treg-mediated effector T cell suppression [52–54].

By removing inhibitory effects of PD-1/PD-L1 pathway, PD-1/PD-L1 blocker enhance antitumor immune responses and exhibit optimal therapeutic efficacy in various tumor types, including melanoma [55], non-small-cell lung cancer [56] and renal-cell cancer [57]. Notably, upregulated PD-1 levels in tumor-infiltrating lymphocytes and PD-L1 levels in tumour cells constitute reliable biomarkers for predicting responses in individuals administered with PD-1/PD-L1 blocker [58–61]. Recently, upregulated PD-1/PD-L1 levels has also been found in patients with myeloid malignancies, including MDS and AML, and both cell culture and animal experiments have strongly suggested potential benefits of PD-1/PD-L1 blocker in preventing progression of these disease [31, 54, 62–66]. However, although numerous preclinical studies have suggested promising efficacy in preclinical MDS/AML models, current clinical outcomes of PD-1/PD-L1 blocker in MDS/AML remains controversial. Exploring roles of PD-1/PD-L1 signaling in BM microenvironment and ameliorating patients’ responses to PD-1/PD-L1 blocker deserves urgent attention.

In the current review, we mainly focus on PD-1/PD-L1 dysregulation in MDS/AML, including the following aspects: (1) the pattern of aberrant PD-1/PD-L1 expression in MDS/AML; (2) the mechanisms by which dysregulated PD-1/PD-L1 signaling influences the BM microenvironment; (3) the mechanisms by which abnormal inflammatory signaling, genetic and/or epigenetic alterations and interactions between cells regulate PD-1/PD-L1 expression; (4) the mechanisms by which drugs, including hypomethylating agents (HMAs), affect PD-1 expression in MDS/AML. Finally, the available outcomes of completed and ongoing clinical trials on PD-1/PD-L1 blocker are reviewed. These studies have examined the therapeutic applications of such molecules either as single or combined agents in MDS/AML.
Dysregulated PD-1/PD-L1 pathway in MDS/AML pathogenesis

Pattern of aberrant PD-1 and PD-L1 expression in MDS/AML

In the past decades, PD-L1 and PD-1 expression in patients’ immune microenvironment have been well investigated. Recent studies have demonstrated that these markers are aberrantly expressed in MDS and AML patients. Detailed results noted that PD-L1 was mainly upregulated in CD34+ blasts, while PD-1 was increased in effector T cells and Tregs [23, 25, 26, 30, 31, 62, 63, 66–79]. Table 1 summarizes current studies focusing on the dysregulated PD-L1 and PD-1 axis in MDS and AML as assessed by flow cytometry.

Identifying specific associations between PD-1/PD-L1 levels and disease status is necessary. Clear description of these aspects could aid the determination of the most suitable time for drug administration in the specific subgroup of patients who are more likely to show good responses to PD-1/PD-L1 inhibition.

In MDS, Kondo et al. indicated that expression of PD-L1 was only observed in individuals with 5% or more blasts, and found a correlation between higher PD-L1 levels and high-risk International Prognostic Scoring System (IPSS) categories [31]. However, some studies reported contradictory findings. Montes et al. observed that PD-L1 levels on peripheral blood (PB) CD34+ cells were comparable between different disease stages of MDS and even higher in MDS than in secondary AML (sAML) [69]. Additionally, Sallman et al. analyzed PD-L1 levels on bone marrow mononuclear cells by flow cytometry and found no association between PD-L1 levels on HSCs, blast percentage in BM, disease progression and Revised International Prognostic Scoring System (IPSS-R) risk categories [80]. Furthermore, although several studies have confirmed upregulated PD-1 on T cells in MDS by flow cytometry [26, 30, 62, 67, 68], it remains unknown whether PD-1 levels are associated with disease progression. Meng et al. detected higher PD-1 level on PB effector T cells in the higher-risk IPSS group [30]. Moreover, Coats et al. analyzed PB PD-1 levels on several T-cell subgroups, e.g., CD4+CD8+ naive T cells, CD4+ TNF-α cells, CD4+ memory cells, CD4+ effector memory cells and Tregs. However, the latter study identified no marked level differences for these markers between the low- and high-risk IPSS-R groups [26].

In AML, most studies [63, 72, 74] but not all [66] found the frequency of PD-L1+ CD34+ cells are comparable between newly diagnosed patients and healthy donors. While in relapsed/refractory (R/R) cases and CR patients with IFN-γ exposure, PD-L1 levels were confirmed to be significantly increased [63, 66, 72, 74]. Further research suggested specific FAB subtype, age, complex cytogenetics and some somatic mutations had significant associations with elevated PD-L1 expression on CD34+ blasts. Zhang et al. found that the AML-M5 subtype showed higher PD-L1 expression than the others [73]. Brodská et al. observed that FLT3 and NPM1 were associated with PD-L1 upregulation [71, 73]; meanwhile, Williams et al. found that AML blasts with TP53 mutation were more frequently positive for PD-L1, which was further confirmed by the studies on MDS and sAML patients by Sallman et al. and Zeidan et al. [75, 80, 81]. However, no correlation of PD-L1 expression with blast load was noted [63, 73, 80]. Notably, researchers also revealed high PD-L1 expression on both PB and BM leukemia blasts upon diagnosis was correlated with poor prognosis [29, 51, 71].

As effector T cells are essential in inducing antitumor immunity, exhausted state of T cells in AML has attracted substantial interest. In BM samples, PD-1 levels on CD4+/8+ T cells and Tregs [78] were found to be significantly increased in newly diagnosed cases and even higher in relapsed AML cases compared with healthy donors (HD), or only restricted on CD4+ T cells in relapsed AML [75]. In PB specimens, studies found PD-1 expressions on CD4+, CD8+ [75], Vδ2+ T cells [77] and Tregs [66] were upregulated in AML patients upon diagnosis, while others argued that PD-1 upregulation on CD8+ T cells [79] were only limited to relapsed cases.

The relationship between frequencies of PD-1+ T cells and survival have also been analyzed. Dong et al. found that elevated PD-1+ Treg rate predicted poor overall survival (OS) and disease-free survival (DFS) [66]. Tang et al. reported that increased percentage of PD-1+ CD8+ T cells in AML patients, both upon diagnosis and after induction chemotherapy, were linked to poor OS and EFS [77].

Several hypotheses have been formulated to explain these discrepant results. Firstly, as MDS and AML are heterogeneous and genetically unstable, the disease state among patients may be genetically different even for the same risk category according to IPSS-R or European LeukemiaNet (ELN) [82, 83]. Secondly, variable treatments received by patients prior to their assessment could influence PD-1 and PD-L1 expressions [68, 84]. Finally, different types of specimens may also lead to the incomparability of results [85]. Additional studies with larger sample sizes are required to obtain definitive results.

Roles of aberrant PD-1/PD-L1 signaling in MDS/AML pathogenesis

In preclinical studies, several roles for PD-1/PD-L1 signaling in MDS/AML have been identified. These evidence offers hypotheses on using PD-1/PD-L1 blocker to suppress disease progression. Several mechanisms underpinning PD-1/PD-L1 signaling dysregulation have
Table 1  Dysregulated PD-L1 and PD-1 expression in MDS/AML

| Disease | Upregulated molecules | Reference | Specimen types and numbers | Cell subtypes with upregulation of PD-1/PD-L1 | Clinical outcome associations |
|---------|----------------------|-----------|-----------------------------|----------------------------------------------|-----------------------------|
| MDS     | PD-L1                | Cheng et al. [62] BM (n = 10) | CD34+ cells; CD33+CD14+ MDSCs; CD71+ erythroid progenitors | NA |
|         |                      | Kondo et al. [31] BM (n = 40) | CD34+ cells | Higher PD-L1 expression was correlated with higher IPSS category |
|         |                      | Tcverkovet al. [67] BM (n = 57) | CD34+ cells | Higher PD-L1 expression was mostly seen during maturation of myeloid blasts into granulocytes |
|         |                      | Yang et al. [68] BM (n = 69) | CD34+ cells | Higher PD-L1 expression was correlated with disease subtypes (MDS 2008 WHO classification) and a trend towards worse survival |
|         |                      | Montes et al. [69] PB (n = 69) | CD34+ cells | Higher PD-L1 expression was seen in MDS rather than sAML |
|         |                      | Moskorz et al. [70] BM (n = 7) | CD34+ cells | Higher PD-L1 expression was seen in CD38+ subset compared to CD38- subset |
|         |                      | Sallman et al. [80] BM (n = 107) | CD34+ cells | PD-L1 expression on HSCs was not correlated with blast percentage in BM, disease progression or IPSS-R risk categories |
|         | PD-1                 | Cheng et al. [62] BM(n = 10) | CD4+/CD8+ T cells; CD34+ HSPCs; CD71+ erythroid progenitors | NA |
|         |                      | Yang et al. [68] PB (n = 24) | PBMCs | Higher PD-1 expression was correlated with older age |
|         |                      | Meng et al. [30] PB(n = 26) | CD4+/CD8+ T cells | Higher PD-1 expression was correlated with higher risk IPSS category |
|         |                      | Coats et al. [26] PB (n = 26) | CD4+ effector memory cells; CD4+ memory cells; CD4+TNF-α secreting cells; CD4+ / CD8+ naive T cells; Tregs | PD-1 expression was not correlated with disease stages |
|         |                      | Tcverkovet al. [67] BM (n = 57) | CD4+/CD8+ T cells | NA |
been implicated in the pathophysiology of leukemogenesis, including conferring PD-L1⁺ CD34⁺ blasts a proliferative advantage, hematopoietic cell apoptosis and immune evasion. Figures 1 and 2 depict these possible mechanisms.

**Proliferative advantage**  The growth of HSCs is controlled in a delicate cell cycle to ensure successful cell division and maintain tissue homeostasis, which is dysregulated in malignant clones [86]. In addition to the known roles of PD-L1 in immune suppression via interaction with PD-1, recent findings have demonstrated that PD-L1 can promote leukemogenesis by activating its own downstream signaling pathway. Kondo et al. observed that PD-L1⁺ blasts isolated from MDS patients exhibited a growth advantage compared with PD-L1⁻ blasts. In addition, PD-L1⁺ cell rate was lower at the static stage (G0/G1 phase) and higher at the synthesis stage (S and G2/M phases) [31]. Further studies demonstrated that these PD-L1⁺ cells incorporated more BrdU and expressed higher Ki-67 level. Consistently, in vitro experiments revealed that increased cyclin D1, D2 and D3 mRNA amounts in PD-L1⁺ cell populations compared with PD-L1⁻ cell populations

![Table 1](https://example.com/table1.png)

**Table 1** (continued)

| Disease | Upregulated molecules | Reference | Specimen types and numbers | Cell subtypes with upregulation of PD-1/PD-L1 | Clinical outcome associations |
|---------|-----------------------|-----------|-----------------------------|-----------------------------------------------|------------------------------|
| AML     | PD-L1                 | Brodská, et al. [71] | PB(n = 36) | CD45dimSSC gating blasts | Higher PD-L1 expression was correlated with poor OS in patients with concomitant FLT3-ITD and NPM1 mutations |
|         |                       | Tamura et al. [72]  | BM (n = 36) | CD34⁺ cells | NA |
|         |                       | Dong et al. [66]   | BM (n = 65) | CD45dimSSC gating blasts | NA |
|         |                       | Zhang et al. [73]  | BM (n = 79) | CD34⁺ cells | Higher PD-L1 expression was observed in AML-MS according to FAB classification, and correlated with a higher relapse rate |
|         |                       | Berthon et al. [63] | BM (n = 79) | CD34⁺ cells | Levels of PD-1 expression was not correlated with NPM1 or FLT3 mutations in newly diagnosed patients; |
|         |                       | Krönig et al. [74] | BM (n = 154) | CD34⁺ cells | Levels of PD-L1 expression was not correlated with blasts load |
|         |                       | Williams et al. [75] | BM (n = 107) | CD34⁺ cells | Higher PD-L1 expression were observed in patients harboring TP53-mutation and complex cytogenetics |
|         | PD-1                  | Wu et al. [76]    | PB (n = 22) | Vδ2 T cells | NA |
|         |                       | Wan et al. [25]   | PB (n = 45) | Tregs | NA |
|         |                       | Tang et al. [77]  | PB (n = 50) | CD4⁺/CD8⁺/γδ T cells | Higher PD-1 expression on CD8⁺ T cells was correlated with poor OS and EFS |
|         |                       | Dong et al. [66]  | BM (n = 65) | Tregs | Higher PD-1 expression on Tregs was correlated with poor OS and DFS, and suggested a trend of higher frequencies PD-L1⁺ blasts in BM |
|         |                       | Daver et al. [78] | BM(n = 74) | CD4⁺/CD8⁺ / Tregs | NA |
|         |                       | Williams et al. [75] | BM (n = 107) | CD4⁺/CD8⁺ | NA |
|         |                       | Schnorfeil et al. [79] | PB (n = 37); BM (n = 44) | CD4⁺/CD8⁺ T cells | Levels of PD-1 expression was not correlated with CMV serostatus |
|         |                       | Tan et al. [23]   | PB (n = 30); BM (n = 15) | CD3⁺ /CD8⁺ | NA |

BM bone marrow, EFS event-free survival, ITD internal tandem duplications, PBMCs peripheral blood mononuclear cells, MDSCs myeloid-derived suppressor cells, NA not applicable, NPM1 nucleophosmin, sAML secondary acute myeloid leukemia, Tregs regulatory T cells
derived from SKM-1 and F-36P MDS cell lines. Higher numbers of PD-L1+ colonies were also found in the colony-forming assay [31]. Similar results were obtained in the AML murine model, and Fang et al. noted that PD-L1 on blasts was critical in promoting leukemogenesis in vivo via CD274/JNK/Cyclin D2 signaling. PD-L1 deletion resulted in significant decrease in leukemia-initiating cells (LICs) count and caused G1 phase arrest. Meanwhile, in PD-L1- cells, there was significantly decreased phosphorylation of JNK/Cyclin D2, which were key regulators in promoting G1-S transition during the cell cycle [87]. Moreover, Ma et al. reported that higher PD-L1 levels on MOLM-13 cells were correlated with higher glycolysis-associated genes expressions, including ALDOA, PGK1, LDHA and HK2, and a higher level of glycolysis was also observed. After transfection with PD-L1-sh1/2, these cells showed significantly high apoptosis rates [51].

**Hematopoietic cell apoptosis** Ineffective hematopoiesis is one of the hallmarks of MDS, leading to blood cytopenias [1]. It was reported that dysregulated PD-1/PD-L1 signaling was responsible for this process [62]. In the bone marrow milieu of MDS, increased PD-L1 and PD-1 levels in CD34+ cells as well as increased PD-1 levels in CD71+ erythroid progenitors were observed. Cheng et al. further demonstrated that coculture of PD-1+ CD71+ erythroid progenitors and PD-1+CD34+ HSPCs with the addition of recombinant human PD-L1 resulted in significantly increased amount of activated caspase-3 in these PD-1+ cells. This induced cell death...
Immunosuppression  The immunosuppressive effect of PD-1/PD-L1 signaling was also notable in leukemogenesis of MDS and AML. Studies showed that PD-L1+ blasts from MDS/AML patients had a higher resistance to effector T cell-mediated killing, which was partially abolished by PD-L1 blockade [31, 63, 64]. In addition, PD-L1 produced by blasts could promote the conversion of Tregs from conventional CD4+ T cells in AML, and upregulated PD-1 on these Tregs [66, 88]. Such Tregs secreted more IL-10 and IL-35, which not only could inhibit effector T cell function, but also were capable of inducing chemoresistance of HL-60 cells to cytarabine, and promoting proliferation of these cells [66]. Zhou and colleagues noted that PD-1/PD-L1 interaction was critical in Treg-induced immunosuppression in vivo. The latter study showed that Tregs from PD-1 KO mice were less capable of dampening the function of WT CD8+ T cells. And the proliferation and function CD8+ T cells were significantly rescued after PD-L1 blockade, followed by the eradication of established AML in the murine model [54].

Nevertheless, Schnorfeil et al. found that in a part of AML cases relapsing after chemotherapy or allo-SCT despite of PD-1 upregulation on both PB CD4+ and CD8+ T cells, proliferation and cytokine production in these PD-1+ effector T cells remained functionally intact [79].
Accordingly, the above findings indicate that PD-1/PD-L1 signaling is critical in promoting leukemogenesis, and further adding PD-1/PD-L1 blocker augment immune response in effector T cells and induce apoptosis in MDS/AML blasts.

**Regulation of PD-1/PD-L1 signaling in MDS/AML**  
As mentioned above, dysregulated PD-1/PD-L1 signaling has vital functions in the BM milieu of MDS and AML. Therefore, it is critical to investigate the mechanisms of PD-1/PD-L1 signaling regulation in MDS and AML. Recent studies have revealed that many factors are implicated in this process, e.g., abnormal inflammatory signaling, genetic mutations or epigenetic alterations and cell–cell interactions.

**Inflammatory signaling**  
Proinflammatory cytokines have long been recognized to affect the pathogeneses of MDS and AML [16, 62, 89–91]. IFN-γ, TNF-α, S100A9, PGN and LPS [19, 63, 92], are dysregulated in patients (especially higher in the lower-risk MDS group) [93–96] and could strongly induce PD-L1 upregulation, suggesting a role for PD-L1 in modulating the immune microenvironment. Kondo et al. indicated that treatment of SKM-1 cells, F-36P cells or MDS blasts with IFN-γ and TNF-α elevated PD-L1 mRNA and protein levels. Additional studies indicated that inhibition of NF-κB could block PD-L1 upregulation mediated by IFN-γ and TNF-α [31], suggesting a vital role for NF-κB signaling in regulating PD-L1 expression. S100A9, which is produced by myeloid-derived suppressor cells (MDSCs) and mediates premature death of HSPCs, exhibits a variable expression pattern at different disease stages of MDS [16, 17, 97]. Cheng et al. found that S100A9 was also implicated in PD-1/PD-L1 upregulation. After exposure to S100A9, PD-1 in CD34+ HSPCs and CD71+ erythroid progenitor cells and PD-L1 on MDSCs were upregulated; further studies indicated MYC activation upon S100A9 exposure, resulting in upregulations of these two molecules [62].

Studies on AML have found that IFN-γ can induce PD-L1 levels on blasts through multiple mechanisms. STAT1/STAT3 and MAPK pathways were implicated, providing variable targets to suppress tumor tolerance and induce immunity against AML [63, 65, 98, 99]. Yoyen-Ermis et al. found that pSTAT3 was upregulated in blasts isolated from MDS/AML patients and THP-1 cell lines after IFN-γ exposure; further investigation showed that Statick, a small-molecule inhibitor of STAT3/STAT1, was efficient in blocking IFN-γ-induced PD-L1 upregulation [65]. By injecting CpG-Stat3 siRNA into mice AML cells, Hossain et al. confirmed that STAT3 was implicated in PD-L1 regulation, and could induce AML cell immunogenicity by upregulating the proportions of CD8+ T cells in vivo [98]. Additionally, the MAPK pathway attributed a role to regulate PD-L1 expression. Studies found that after exposure to IFN-γ, blasts from AML patients and murine models showed increased PD-L1 expression, which was blocked by MEK inhibitor [63, 99].

**Genetic or epigenetic alterations**  
Inflammatory signaling is not the only stimulus linked to PD-1 and PD-L1 dysregulation in MDS/AML. In addition to extrinsic cellular factors, TP53 alteration was also reported to impact PD-L1 expression [80]. Sallman et al. demonstrated that TP53-mutant HSCs derived from MDS/AML expressed more PD-L1 with concomitant overexpression of MYC and downregulation of miR-34a. The latter played a major role in MYC degradation [80]. Notably, in the latter study, although HSCs and hematopoietic progenitor cells (HPCs) expressed CD34 and harbored TP53 mutations, increased PD-L1 expression was largely restricted to HSCs, with no significant difference in HPCs, suggesting that a more accurate classification of CD34+ cells for evaluating PD-L1 expression was required. Furthermore, miR-34a played a role in suppressing PD-L1 expression by binding to the 3′UTR region of PD-L1 mRNA [100]. Pyzer et al. found that silencing of MUC1 in THP-1 and MOLM-14 cells caused significant PD-L1 downregulation [101]. Further studies demonstrated that the underlying mechanism was mediated by c-Jun activity suppression, which in turn downregulated the microRNA-processing protein DICER and ultimately upregulated miR-200c and miR-34a, which negatively regulated PD-L1 levels in AML, as also noted by other studies [62, 80, 101]. In addition, epigenetic alterations also play an essential role in regulating PD-1/PD-L1 expression in MDS/AML. Previous studies reported that following a prolonged TCR stimulation in CD8+ T cells, promoter of PD-1 was demethylated, which further upregulated PD-1 level [102]. Recently, HMAs have been shown to exert epigenetic immunomodulatory and demethylation effects on tumor cells [103]. Their capacity to upregulate PD-1 on effector T cells in some MDS/AML patients was also noted [68, 84]. Further studies focusing on the mechanisms by which HMAs influence PD-1 expression are warranted.

**Cell interactions**  
In AML, PD-1 expression on effector T cells is modulated at the protein level by interactions between cells. CD200, overexpressed in AML blasts with a suppressive role in the antitumor response [104], was also recently observed to be linked to PD-1 expression [105]. Coles et al. indicated that CD8 T cells from CD200hi AML patients showed higher levels of PD-1, almost twice, compared with CD200lo patients. Further in vitro assays suggested that CD200-CD200R interactions could lead to a significant PD-1 level upregulation on CD8+ T cells [106].
DCs were also found to be implicated in PD-1 expression regulation [107]. Lecciso et al. examined a cohort of AML patients and found that PD-1+ Tregs were significantly increased after combined daunorubicin and cytarabine chemotherapy. Further in vitro investigation revealed that ATP was critically involved in PD-1 upregulation, which was released from AML cells after daunorubicin treatment. When DCs were treated with ATP or cocultured with daunorubicin-treated AML cells, indoleamine 2,3-dioxygenase 1 (IDO1) was upregulated in DCs, which could induce PD-1+ Tregs. Notably, in vivo studies showed that in ATP receptor-lacking mice, daunorubicin failed to induce IDO1-expressing DCs and Tregs generation [107].

**Association of dysregulated PD-1 and PD-L1 expression with HMA resistance**

HMAs, including azacitidine (AZA) and decitabine (DAC), are the most common first-line treatment options for higher-risk MDS patients and older/unfit AML patients. However, approximately 50% of patients showed responses to these agents, with usually a transient duration [108]. Patients who lost responses to HMAs exhibited particularly poor survival, with an estimated median OS of 4.3~5.6 months [109, 110]. The mechanisms of resistance to HMAs in the setting of MDS have been actively explored. Diverse molecular mechanisms contributing to HMA resistance have been proposed, including integrin α5-mediated hematopoietic progenitor cell quiescence [111], elevated CDA/DCK ratio [112], increased RNA:m5C and NSUN1-/BRD4-associated active chromatin [113], elevated BCL2L10 expression (114), disturbed STAT3/5 signaling [115] and high number of mutations in the DNA methylation pathway, notably in TET2 gene [116–119].

Recent studies have identified a correlation between HMA resistance and dysregulated PD-1/PD-L1 signaling. Both PD-1 and PD-L1 levels indicated an increased trend in peripheral blood mononuclear cells (PBMCs) of MDS/AML patients with no response to HMAs [68]. Notably, although baseline PD-1 expression was comparable between responders and non-responders, methylation in PD-1 promoter was markedly enhanced in the latter group, which had a more dynamic change of demethylation in the PD-1 promoter region and higher PD-1 protein expression (68). Furthermore, since PBMCs were composed of different cell subpopulations in addition to T cells, Orskov et al. demonstrated that baseline PD-1 promoter methylation in effector T cells was higher in non-responders. In addition, individuals with higher demethylation levels in the PD-1 promoter exhibited a shorter OS, in accordance with poor survival noted in HMA-failure patients [84]. Furthermore, Yang et al. modeled the data in vitro and demonstrated that HMAs induced the upregulation of PD-L1 in KG-1 and THP-1 cells [68]. Upregulation of NF-κB and increased IFN-γ sensitivity were suggested to be responsible for this effect [120, 121].

Figure 3 summarizes the immune microenvironment of the BM in HMA-failure MDS/AML patients. Given that resistance to HMAs may be mediated by increased PD-1/PD-L1 signaling, combining PD-1/PD-L1 blocker and HMAs was suggested for the treatment of the patients.

**Available clinical outcomes of PD-1/PD-L1 blockade-based therapy in MDS/AML**

Based on preclinical findings that demonstrate PD-1 and PD-L1 are upregulated in MDS and R/R AML, especially in patients developing resistance to HMAs, the efficacy of several monoclonal antibodies targeting this pathway as single agent or combination therapies in treatment-naïve patients developing resistance to HMAs. The efficacy of nivolumab was also evaluated in MDS patients following HMA failure in a phase II trial, which enrolled 28 patients from 50 to 5%. No trial employing pidilizumab has been conducted in MDS/AML subsequently [122]. Other PD-1/PD-L1 inhibitor examined in MDS include pembrolizumab, nivolumab and atezolizumab, which have shown encouraging clinical outcomes such as long-term survival in solid tumors [123–126]. In MDS, pembrolizumab monotherapy was examined in a phase Ib study (NCT01953692), which enrolled 28 MDS patients following failed responses to hypomethylating agents [127]. A total of 5.6-month median follow-up was conducted, and the overall response rate (ORR) was only 4%, with an OS rate of 49% at 24-week. The efficacy of nivolumab was also evaluated in MDS patients following HMA failure in a phase II trial, which used this antibody as a monotherapy-based agent (NCT02397720) [128]. No CR was detected, and only two patients achieved partial response (PR) (13% ORR) among 15 patients, and the median OS was 8 months. Although the efficacy of PD-1 antibodies used as monotherapy was unimpressive in HMA-failure cohorts, their safety profile was generally favorable in these trials and no treatment-related deaths were reported [128]. However, a phase Ib trial on atezolizumab, the
only PD-L1 antibody that was examined as a mono-
therapy agent in MDS patients following HMA failure,
reported 70% (7/10) of patients did not survive after a
160-day median follow-up, mainly due to disease pro-
gression [129].

Although preclinical studies suggested potential ben-
efits of PD-1/PD-L1 blocker for MDS/AML, especially
after HMA failure, current clinical outcomes after apply-
ing such agents as monotherapy were disappointing. The
causes of this discrepancy between preclinical studies
and clinical trials are under investigation. The dynamic
changes in the immune microenvironment of the bone
marrow may be critical, as previous studies have reported
that some individuals with promoter-demethylated PD-1
gene during HMA therapy develop a diverse remethyla-
tion pattern in the same loci before the next treatment
cycle [84]. Other potential explanations of this discrep-
ancy may be that the majority of available trials enrolled
high-risk patients with a heavy disease burden and
advanced tumor stage, which also reflects a poor progno-
sis [130].

**Combination therapy of PD-1/PD-L1 inhibitor in MDS/AML**

Although preclinical investigations suggested potential
synergistic effects of HMAs or intensive chemotherapy
and PD-1/PD-L1 inhibitor, current clinical trials reported
mixed responses, with data mostly unimpressive in
HMA-failure and R/R patients.

In a phase II study including 70 R/R AML patients (25
HMA-naive and 45 HMA-failure) treated with AZA and
nivolumab, the ORR was 33% (58% and 22% for HMA-
aive and HMA-failure, respectively), the CR/CRi rate
was 22%, and the median OS was 6.3 months [131]. The
authors reported that the outcomes were better in this
trial than those described in a historical cohort study
performed in the same institution with an ORR of 20%
after HMA-based salvage therapy for 172 R/R AML
patients [131]. Notably, after 2 and 4 doses of nivolumab,
CTLA-4 levels were markedly increased on CD4+ T cells
in non-responders [131].

Another phase II trial (NCT03094637) assessed the
synergistic effects of pembrolizumab and AZA in MDS.
Totally, 37 MDS patients (17 HMA-naive and 20 HMA-
failure) with IPSS intermediate-1 or higher-risk disease
were enrolled. The ORRs were 76% in HMA-naive cohort
and 25% in the HMA-failure cohort, with a CR of 18%
Table 2  Available results of clinical trials for PD-1/PD-L1 inhibitor in treatment of MDS/AML

| Reference                    | Trial phase | Patient characteristics                                                                 | Intervention | Target | Efficacy | Toxicity                                                                 |
|------------------------------|-------------|------------------------------------------------------------------------------------------|--------------|--------|----------|----------------------------------------------------------------------------|
| Berger et al. [122]          | I, single-arm | 8 R/R AML (4 AML relapsed after allo-SCT) and 1 MDS                                      | CT-011 (0.2–6 mg/kg) | PD-1   | One AML patient achieved peripheral blasts reduction | 50% AML patients experienced grade 3–4 AEs and died (due to fulminate resistant leukemia but not study drug) |
| Garcia-Manero et al. [127]   | Ib, single-arm | 28 HMA-failure MDS                                                                       | Pembrolizumab 10 mg/kg, Q2weeks | PD-1   | ORR 4%; CR 0% OS rate 49% at 24 weeks | Hypothyroidism (14%), fatigue (11%), 7% grade 3/4 treatment-related AEs; 1 gastroenteritis (grade 3) and 1 TLS (grade 4) |
| Garcia-Manero et al. [128]   | II, multi-arms non-randomized | 15 HMA-failure MDS                                                                       | Nivolumab 3 mg/kg on day 1 and 15 Q4weeks | PD-1   | ORR 35%; CR/CRp 15%; mOS NR | Skin rash (11%), fatigue (9%), pain (7%), infection (6%); FN (5%), pruritus (6%); diarrhea (5%); constipation (4%); nausea (4%); ALT elevations (3%); anorexia (3%); and cough (3%) |
|                              |             | 20 HMA-failure MDS                                                                       | Ipilimumab 3 mg/kg Q3weeks | CTLA-4 | ORR 13%; CR/CRP 0%; mOS 8 mos | One early mortality |
|                              |             | 20 treatment-naive MDS                                                                  | Nivolumab 3 mg/kg on day 6 and 20, plus AZA 75 mg/m² daily for 7 days Q4weeks | PD-1 + HMA | ORR 75%; CR/CRP 50%; mOS 12 mos | |
|                              |             | 21 treatment-naive MDS                                                                  | Ipilimumab 3 mg/kg on day 6, plus AZA 75 mg/m² daily for 7 days Q4weeks | CTLA-4 + HMA | ORR 71%; CR/CRP 38%; mOS 8 mos | |
| Chien et al. [132]           | II, single-arm | 17 treatment-naive MDS                                                                  | Pembrolizumab 200 mg Q3weeks, plus AZA 75 mg/m² daily for 7 days Q4weeks | PD-1 + HMA | ORR 76%; CR 3%; mOS NR | Arthralgias (40%), pneumonia (33%), nausea (27%). One patient died within first 60 days due to unrelated cause of ventricular fibrillation |
|                              |             | 20 HMA-failure MDS                                                                       | Pembrolizumab 200 mg Q3weeks, plus AZA 75 mg/m² daily for 7 days Q4weeks | PD-1 + HMA | ORR 25%; CR 5%; mOS 5.8 mos | Pneumonia (32%); arthralgias (24%); constipation (24%). Two patients died within first 60 days |
| Daver et al. [131]           | II, single-arm | 70 R/R AML (25 HMA-naive and 45 HMA-failure)                                           | Nivolumab 3 mg/kg on day 1 and day 14, plus AZA 75 mg/m² daily for 7 days Q4-6 weeks | PD-1 + HMA | ORR 33% (58% in HMA-naive, 22% in HMA-failure patients); CR/CRI was 22%; mOS 6.3 mos | 23% grade > 2 immune toxicities, 9 pneumonitis, 6 nephritis, 3 immune related skin rash, and 2 transaminitis |
| Gerds, et al. [129]          | Ib, multi-arm non-randomized | 10 HMA-failure MDS                                                                       | Atezolizumab 1200 mg Q3weeks | PD-L1  | ORR 0%; CR 0% mOS 5.9 mos | 10% grade > 3 FN; 0% died (10% occurred within 3 months) |
|                              |             | 11 HMA-failure MDS                                                                       | Atezolizumab 1200 mg Q3weeks plus AZA 75 mg/m² daily for 7 days Q4weeks | PD-L1 + HMA | ORR 9%; CR 0% mOS 10.7 mos | 36% grade > 3 FN; 64% died (18% occurred within 3 months) |
|                              |             | 21 treatment-naive MDS                                                                  | Atezolizumab 840 mg Q2weeks plus AZA 75 mg/m² daily for 7 days Q4weeks | PD-L1 + HMA | ORR 62%; CR 14% mOS NR | 33% grade > 3 FN; 29% died (all occurred within 3 months) |
Table 2 (continued)

| Reference                  | Trial phase               | Patient characteristics | Intervention                                                                 | Target       | Efficacy             | Toxicity                                                                 |
|----------------------------|---------------------------|-------------------------|-------------------------------------------------------------------------------|--------------|----------------------|--------------------------------------------------------------------------|
| Zeidan, et al. [134]       | II, multi-arms randomized controlled | 42 treatment-naïve MDS  | Durvalumab 1500 mg Q4weeks plus AZA 75 mg/m² daily for 7 days Q4weeks       | PD-L1 + HMA | ORR 61.9%; CR 7.1%; mOS 11.6 mos | Most common treatment-emergent AEs were hematologic and gastrointestinal toxicity. Immune-mediated AEs were observed in 7 MDS and 17 AML patients |
|                            |                           | 42 treatment-naïve MDS  | AZA 75 mg/m² daily for 7 days Q4weeks                                        | HMA          | ORR 47.6%; CR 9.5%; mOS 16.7 mos; |
|                            |                           | 64 treatment-naïve AML 1–7 every 4 weeks | Durvalumab 1500 mg Q4weeks plus AZA 75 mg/m² daily for 7 days Q4weeks | PD-L1 + HMA | ORR 31.3%; CR 17.2%; mOS 13.0 mos; |
|                            |                           | 65 treatment-naïve AML  | AZA 75 mg/m² daily for 7 days Q4weeks                                        | HMA          | ORR 35.4%; CR 21.5%; mOS 14.4 mos; |
| Zeidner et al. [136]       | II, single arm            | 37 R/R AML              | HIDAC 1.5/2 gm/m² daily for 5 days plus Pembrolizumab 200 mg on day 14. Responders were continued to receive pembrolizumab 200 mg Q3weeks | PD-1 + chemotherapy | ORR 46%; CR 38%; mOS 8.9 mos | Most frequent grade > 3 pembrolizumab-related toxicities were ALT elevation (n = 1), AST elevation (n = 1), and grade > 3 maculopapular rash (n = 2). One patient did not survive due to disease progression within sixty days |
| Ravandi et al. [137]       | II, single arm            | 44 treatment-naïve (42 AML and 2 high-risk MDS) | cytarabine 1.5 g/m² daily for 4 days and idarubicin 12 mg/m² daily for 3 days, plus Nivolumab 3 mg/kg on day 24 ± 2 and continued Q2weeks | PD-1 + chemotherapy | ORR 80%; CR 78%; mOS 18.54 mos | 6 patients had seven grade 3/4 IRAE with rash (n = 2), colitis (n = 2), transaminitis (n = 1), pancreatitis (n = 1) and cholecystitis (n = 1) |

AE adverse events, AZA 5-azacytidine, CR complete response, CRp CR with incomplete platelet recovery, FN febrile neutropenia, HiDAC high dose cytarabine, IRAE immune-related adverse events, mOS median overall survival, NR not reached, ORR overall response rate, SAE serious adverse event, TLS tumor lysis syndrome
and 5%, respectively [132]. Notably, one HMA-failure patient who harbored 2 separate TP53 gene mutations experienced stable disease with transfusion independence for more than 34 months in this trial, and ASXL1 and SETBP1 gene mutations were most frequently found in responders of the HMA-failure cohort, while TET2, ASXL1 SRSF2 and RUNX1 gene mutations were detected in the HMA-naïve cohort [132, 133]. Garcia-Manero et al. reported the outcomes after administering nivolumab with AZA in a phase II trial [128]. The trial enrolled 20 treatment-naïve MDS patients, and found an ORR of 75% and a CR/CRp of 50%. The median OS was 12 months [128]. Still, the safety profile of PD-1 blocker in combination with HMAs was favorable in these trials. While in the phase Ib trial employed atezolizumab combined with AZA (NCT02508870) [129] in 32 high-risk MDS patients (21 HMA-naïve and 11 HMA-failure), although a relatively high response was reported in the HMA-naïve cohort with an ORR of 62% and a CR of 14%, an unexpected early mortality was noted. Six patients (29%) did not survive within 3 months after therapy initiation, owing to serious treatment-related adverse events (AEs) [129]. In the HMA-failure cohort, a modest response was reported with an ORR of 9%, no CR, and a median OS of 10.7 months. Totally, 7 patients (64%) did not survive because of disease progression, with a median survival time of 299 days [129]. Unexpected early mortality rate led to early termination of this trial.

Currently, only one randomized trial conducted on PD-1/PD-L1 inhibition therapy for treatment-naïve MDS/AML patients, and reported similar outcomes compared to the HMA-naïve cohorts in the above-mentioned trial [134]. In a phase II trial (NCT02775903), a total of 84 higher-risk MDS and 129 older AML (aged ≥ 65 years) patients were enrolled. Patients were randomly grouped to receive either durvalumab in combination with AZA or AZA alone. The ORR was merely improved in the PD-L1 inhibitor combination group versus the AZA monotherapy group (61.9% and 31.3% in the MDS and AML cohorts in the combination group, respectively, vs. 47.6% and 35.4% in the MDS and AML cohorts in the AZA alone group, respectively), whereas no improvement was found in median OS (11.6 and 13.0 months in MDS and AML patients in the combination group, respectively, vs. 16.7 and 14.4 months in MDS and AML patients in the AZA alone group) [134]. In this trial, importantly, although PD-L1 gene promoter demethylation was confirmed in patients following AZA administration, PD-L1 protein expression upregulation in blasts was not observed [134].

In addition to HMAs, intensive chemotherapy was also suggested to potentially exert synergistic effects with PD-1/PD-L1 blocker [107, 135]. In a phase II trial, 37 R/R AML patients were administered with high dose cytarabine in combination with pembrolizumab, and ORR was 46% and CR rate was 38%, with an 8.9 months median OS. AEs including febrile neutropenia (FN) (57%), ALT elevation (43%) and AST elevation (32%) were most commonly seen. One patient did not survive due to disease progression within 60 days [136]. In another single-arm phase II trial, 44 treatment-naïve patients (42 AML and 2 high-risk MDS) were treated with cytarabine, idarubicin and nivolumab; the ORR was 80%, and 78% patients achieved CR [137]. Median OS was 18.54 months, with no significant improvement compared to a contemporary cohort examining cytarabine plus idarubicin [137, 138]. Notably, analysis conducted in this trial showed that non-responders had markedly elevated percentage of bone marrow CD4+ T cells co-expressing PD-1/TIM-3 in comparison with responders [137]. Accordingly, the above data suggested PD-1/PD-L1 blocker combined with HMAs or chemotherapeutics could yield more promising results in treatment-naïve patients, whereas they could also increased the frequency of AEs compared with single agents. Although the patients administered with combination therapy showed more promising responses, only a modest improvement was seen compared with historical controls. The factors accounting for these discrepancies between preclinical studies and clinical trials are not completely understood. Reasonable explanations may include differences between disease models and patients, as the immune microenvironment in patients is more complex with various groups of immune cells and mesenchymal cells. It should also be noted that MDS and AML are a group of highly heterogeneous diseases, and genetic subtypes are usually different among patients, even in the same risk group. Patients who carry specific somatic mutations, including TP53, ASXL1, SETBP1, TET2, SRSF2 and RUNX1 gene mutations, are more likely to respond to PD-1/PD-L1 inhibitor [133, 139]. Next-generation sequencing (NGS) is rapidly changing the clinical decision-making process in MDS/AML [140–144]. The use of NGS and its combination with further molecular data may yield a high predictive power. Furthermore, double or more immune checkpoint inhibitor (ICI)-based combination therapies may be more efficient. Finally, most of the trials mentioned above are non-randomized studies with inadequate sample size, and more comparative and randomized trials with larger sample size across different patient populations and longer follow-up periods are required in the future.
Ongoing trials exploring PD-1/PD-L1 blockade-based strategies

Since current trials have reported limited efficacy of PD-1/PD-L1 blocker in MDS/AML, numerous ongoing efforts are being made for assessing the effectiveness of novel combinations, including with novel HMAs, other immune checkpoint inhibitors (ICIs), histone deacetylase inhibitors (HDACi), tumor vaccines or chemotherapeutic agents (Table 3). In general, several challenges are under investigation. Firstly, in NCT03092674, a randomized II/III phase study with approximately 1,670 participants, the efficacy of nivolumab alone or in combination with AZA for a large MDS patient population was examined. Secondly, in addition to patients in frontline or relapsed/refractory setting, PD-1/PD-L1 blockade are also being examined for effectiveness in MDS/AML relapsing after allogeneic hematopoietic stem cell transplantation (allo-HSCT) or individuals at high risk of relapse in NCT03286114, NCT02981914, NCT02532231, NCT03600155, NCT02846376 and NCT02771197. It should be noted that although previous reports have demonstrated increased efficacy of PD-1/PD-L1 blocker in MDS/AML cases after allo-HSCT, unfavorable high risk of graft-versus-host disease (GVHD) was also reported [145–147]. The optimal dose of nivolumab for alleviating graft-versus-leukemia (GVL) without severe GVHD induction required to be defined. Thirdly, researchers are also interested in exploring optimal managements of HMA in combination with PD-1/PD-L1 inhibitor, including the optimal dose, administration time and delivery methods (NCT03969446 and NCT02281084), as well as other novel HMAs (NCT02935361 and NCT02892318). Furthermore, PD-1/PD-L1 inhibitor are also examined in combination with other immunotherapeutic agents, including LAG-3 inhibitor, (NCT04913922), CTLA-4 inhibitor (NCT02530463), TIM-3 inhibitor (NCT03066648), CD47 inhibitor (NCT03922477), CD-33 and OX-40 inhibitor (NCT03390296), tumor vaccines (NCT03358719) or chemotherapy (NCT04541277, NCT04214249, NCT04722952 and ChiCTR2100045296). Finally, combinations of PD-1 inhibitor with HDACi are also being studied (NCT02936752, NCT04277442 and NCT04284787).

Future perspectives

It is increasingly clear that PD-1/PD-L1 blocker-based treatment in MDS/AML faces overt challenges. Firstly, reliable biomarkers are necessary for predicting and tracking the responses of patients. Although a previous study has reported higher CD3+ T cells ratio in PB and BM samples from AML patients as a predictive biomarker [131], a large room for improvement remains. In solid tumors, predictive biomarkers of PD-1/PD-L1 blocker have been studied extensively. Soluble PD-L1 (sPD-L1), which is produced by DCs and cancer cell lines in vitro, has potential as a predictive biomarker [148]. Studies reported that elevated baseline sPD-L1 level is correlated with lower response rate of PD-1/PD-L1 inhibitors in non-small-cell lung cancer cases [149, 150]. DNA mismatch repair (MMR), which is vital for the maintenance of genomic stability, has been identified to play critical roles in the pathogenesis of AML [151]. Recent findings have suggested that a high degree of microsatellite instability can predict patient response to PD-1 blocker in colorectal cancer [152]. IFN-γ is secreted by activated CD8+ T cells to inhibit tumor cell proliferation, while it also upregulates PD-L1 on these cells [153]. Recent studies also have shown that melanoma patients with elevated baseline levels of IFN-γ exhibit a higher potential to respond to these agents [154, 155]. Therefore, the dynamic monitoring of PD-L1 expression during therapy can be used as an indirect assessment of the efficacy of PD-1/PD-L1 inhibitor, which exerts functions by restoring CD8+ T cell activation. Other biomarkers, including immunoscore, tumor mutational burden, gut microbiota and additional peripheral cytokines are being assessed eagerly, although their application values remain largely unclear in MDS/AML [156].

Moreover, peripheral blood cytopenia and decreased number of functional effector T cells are common signs of MDS/AML, abrogating the immune system, whereas pre-existing TILs are considered a critical factor for predicting a durable response to PD-1/PD-L1 blocker [157, 158]. Effective immune reconstitution and low disease burden following SCT may provide an ideal setting [159]. Therefore, PD-1/PD-L1 blockade following allo-HSCT is suggested, which may achieve a competent immune system to fully eradicate the underlying malignancy.

In addition to the aforementioned hypotheses, T cell regulation is an extremely complex process involving multiple inhibitory checkpoint molecules [160, 161]. Although PD-L1 expression is increased in MDS/AML blasts, and elevated PD-L1 expression on malignant cells is generally considered a reliable biomarker for predicting response to PD-1/PD-L1 blocker, a high number of MDS/AML patients do not fully benefit from these agents. Notably, recent evidence has suggested that PD-1/PD-L1 upregulation in MDS/AML patients less mediates the upfront tumor immune escape than reflects an adaptation resistance of tumor cells to the ongoing anticancer immunity, which is accompanied by PD-1 upregulation, co-expression of other immune checkpoints on effector T cells including TIM-3 [53, 137, 162], LAG-3 [75, 137], CTLA-4 [131, 163] and TIGIT [27]. Therefore, it may be difficult to achieve promising results by simply blocking PD-1/PD-L1 signaling alone.
Table 3  Ongoing clinical trials for immune checkpoint inhibitors in treatment of MDS/AML

| Phase | Inclusion | Therapy | Target | Primary objectives | Reference |
|-------|-----------|---------|--------|-------------------|-----------|
| Ib    | Relapsed MDS/AML/ALL after allo-SCT | Pembrolizumab | PD-1 | CR, PR, SD, toxicity | NCT03286114 |
| Early I | Relapsed MDS/AML/Hodgkin and non-Hodgkin lymphoma after allo-SCT | Pembrolizumab | PD-1 | AEs | NCT02981914 |
| II    | High risk for relapse AML | Nivolumab | PD-1 | RFS | NCT02532231 |
| Ib    | Relapsed MDS/AML after allo-SCT | Nivolumab and/or Ipilimumab | PD-1 and/or CTAL-4 | MTD, DLTs, toxicity | NCT03600155 |
| I     | High risk for relapsed MDS/AML after allo-SCT | Nivolumab and/or Ipilimumab | PD-1 and/or CTAL-4 | Safety | NCT02846376 |
| II    | Non-favorable risk AML | Pembrolizumab + Flu/ Mel + Allo-SCT | PD-1 + Lymphodepletion + allo-SCT | RFS | NCT02771197 |
| I     | Previously untreated and relapsed/refractory MDS/AML | Pembrolizumab + DAC | PD-1 + HMA | AEs, MTD, CR/CRi | NCT03969446 |
| II/III | Previously untreated higher-risk MDS | Nivolumab + AZA/AZA | PD-1 + HMA | OS | NCT03092674 |
| II    | R/R AML | Pembrolizumab (GHR-1210) + DAC | PD-1 + HMA | ORR, CR | NCT04353479 |
| 0     | Previously untreated higher-risk MDS | Sintilimab + DAC | PD-1 + HMA | ORR | ChiCTR2100044393 |
| II    | Higher-risk MDS | Camrelizumab + DAC | PD-1 + HMA | ORR | ChiCTR1900028440 |
| IV    | MDS-EB1/2 | PD-1 monoclonal antibody + AZA | PD-1 + HMA | Efficacy | ChiCTR2000034927 |
| IV    | HMA failure MDS | Camrelizumab + DAC | PD-1 + HMA | ORR | ChiCTR2100044210 |
| II    | previously untreated AML/sAML | Pembrolizumab + Ara-C + IDA/ DNR | PD-1 + chemotherapy | MDR-CR | NCT04214249 |
| II    | R/R AML excluding relapsed after HSCT | Tislelizumab + CAG | PD-1 + chemotherapy | ORR | NCT04541277 |
| –     | Higher-risk MDS | Tislelizumab + HMA + cytarabine | PD-1 + HMA + chemotherapy | Efficacy | ChiCTR2100045296 |
| III   | R/R AML | Sintilimab + HAA + ICI | PD-1 + HMA + chemotherapy | ORR, CR, PR | NCT04722952 |
| II    | R/R AML | Pembrolizumab + AZA + Relatlimab | PD-1 + LAG-3 | MTD, DLTs, ORR | NCT04913922 |
| II    | Previously untreated or HMA failure MDS | Pembrolizumab + nivolumab + Ipilimumab + AZA | PD-1 and/or CTAL-4 and/or HMA | ORR | NCT02530463 |
| I     | AML and intermediate or high-risk MDS | PDR001 + DAC and/or MBG453 | PD-1 + TIM-3 and/or HMA | AEs, DLTs | NCT03066648 |
| Ib/II | R/R AML | Pembrolizumab + AZA + GO/VEN anti-OX40 antibody | PD-1 + CD33 + HDAci | AEs | NCT03390296 |
| Ib    | HMA failure MDS | Pembrolizumab + entinostat | PD-1 + HDAci | MTD | NCT02936752 |
| I     | Untreated AML with TP53-mutated | Pembrolizumab + nivolumab + Ipilimumab + AZA | PD-1 + HMA + HDACi | CRc | NCT04277442 |
| II    | previously untreated AML/sAML with ≤ 30% blasts | Pembrolizumab + AZA + VEN | PD-1 + HMA + HDACi | MTD-CR | NCT04284787 |
| I     | Higher-risk MDS or AML with ≥ 30% blasts | Pembrolizumab + DAC + NY-ESO-1 vaccination | PD-1 + HMA + tumor vaccine | Safety | NCT03358719 |
| II/II | Higher-risk MDS/CML with HMA-failure | Pembrolizumab + guadecitabine | PD-1 + HMA | DLTs, ORR | NCT02935361 |
| II    | MDS with post injectable HMA-failure | Pembrolizumab + guadecitabine | PD-1 + HMA | ORR | NCT02281084 |
| I     | AML | Pembrolizumab + guadecitabine | PD-1 + HMA | AEs, CR, CRp, CRi, DOR | NCT02892318 |
| I     | R/R AML | Pembrolizumab + Hu5F9-G4 | PD-1 + CD47 | AEs, CR, DOR | NCT03922477 |

* Allo-SCT allogeneic stem cell transplantation, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CR complete remission with incomplete count recovery, CRc composite complete response, DLTs dose-limiting toxicities, DOR duration of response, MTD maximum tolerated dose, RFS recurrence-free survival, SD stable disease
* NY-ESO-1 vaccination: Anti-DEC-205-NY-ESO-1 fusion protein plus poly-ICLC
Combination of PD-1/PD-L1 inhibitor with other ICIs has been suggested [76, 164–167]. Other immune checkpoints (Fig. 4), e.g., CTLA-4 [68, 131, 163], TIM-3 [53, 162, 168–171], CD47 [172–174], LAG-3 [32, 75] and TIGIT [27, 30], have all been shown to be upregulated in MDS/AML patients. Several trials have assessed efficacy of these ICIs in treating MDS/AML, with promising preliminary results. The NCT02530463 trial assessed the efficacy of a double immune checkpoint inhibition by both CTLA-4 and PD-1 in the treatment of MDS. In the HMA-failure cohort with a 25-month median follow-up, the ORR was 36%, including 9% CR (1/11), 9% CRi (1/11) and 18% HI (2/11) [175]. In NCT03066648, the efficacy of a TIM-3 inhibitor in combination with DAC was assessed in 17 treatment-naïve HR-MDS and 38 AML patients. An encouraging result was reported with 50% MDS patients achieving mCR or CR, 14% and 14% newly diagnosed AML patients showing CR and PR, and 29% R/R AML patients achieving CRi [176]. Surprisingly, the anti-CD47 antibody magrolimab yielded encouraging outcome for the treatment of MDS/AML [177, 178]. In a phase Ib trial, 43 treatment-naïve patients (18 MDS and 25 AML) were treated with magrolimab in combination with AZA. In the MDS cohort, the ORR was 100%, with 54% cases achieving CR and 39% showing marrow CR. In the AML cohort, the ORR was 69%, with 50% cases showing CR or CRi. A good safety profile was also reported with most common AEs being anemia (37%), neutropenia (26%) and thrombocytopenia (26%). Only 1 patient developed treatment-related febrile neutropenia, and only 1 case had treatment discontinuation due to AEs [178]. Additional translational studies are needed to clarify roles of immune checkpoint blockade therapy in MDS/AML.

**Conclusion**

Currently, novel treatment strategies beyond epigenetic drugs are highly required for the treatment of MDS/AML. The remarkable development of immune checkpoint...
therapy provides a novel therapeutic strategy. Inflammatory signaling pathways have been found to play central roles in leukemogenesis, which draws additional attention into the role of dysregulated immune checkpoints. Recent studies have found PD-1/PD-L1 are upregulated in MDS/AML patients and play vital roles in the pathogenesis of this disease. Further preclinical studies also reported the efficacy of PD-1/PD-L1 blocker in MDS/AML models and suggested a potent clinical efficacy. However, available clinical studies assessing PD-1/PD-L1 blockade have reported modest outcome improvement in MDS/AML patients. Future challenges include identifying reliable biomarkers, exploring more optimal combination therapies, and determining the subgroups of patients who might benefit from PD-1/PD-L1 blocker. Furthermore, as other immune checkpoints (CTLA-4, TIM-3 and CD47) are also co-expressed with PD-1 in MDS/AML, future studies focusing on the interactions between different immune cells and immune checkpoint molecules in MDS/AML are warranted, and designing more reasonable dual or triplet combination therapies may also help.

**Abbreviations**
AEs: Adverse events; allo-HSCT: Allogeneic hematopoietic stem cell transplant; ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; AZA: Azacitidine; CR: Complete response; Crp: CR with incomplete platelet recovery; CTLA-4: Cytotoxic T-lymphocyte-associated protein-4; DAC: Decitabine; DLTs: Dose-limiting toxicities; MMR: Mismatch repair; ELN: European LeukemiaNet; FN: Febrile neutropenia; GVHD: Graft-versus-host disease; HD: Healthy donors; HDACi: Histone deacetylase inhibitors; Hidac: High dose cytarabine; HMAs: Hypomethylating agents; HSPCs: Hematopoietic progenitor cells; HSCs: Hematopoietic stem cells; IDO1: Indoleamine 2,3-dioxygenase 1; IFN-γ: Interferon-γ; ILCs: Leukemia-initiating cells; IL-6: Interleukin-6; IRAE: Immune-related adverse events; IPSS: International Prognostic Scoring System; IPSS-R: Revised International Prognostic Scoring System; MDS: Myelodysplastic syndromes; MDScs: Myeloid-derived suppressor cells; MHC: Major histocompatibility complex; MT: Mutation; MTD: Maximum tolerated dose; NGS: Next-generation-sequencing; NPM1: Nucleophosmin; ORR: Overall response rate; OS: Overall survival; PBMCs: Peripheral blood mononuclear cells; R/R: Relapsed/refractory; PD-1: Programmed cell death-1; PD-L1: Programmed cell death ligand-1; PR: Partial response; SAE: Serious adverse event; SAML: Secondary AML; SD: Stable disease; sPD-L1: Soluble PD-L1; STAT3: Signal transducer and activator of transcription 3; TCR: T-cell receptor; TIGHT: T-cell immunoglobulin mucin-3; TLS: Tumor Lysis syndrome; TNF-α: Tumor necrosis factor-α; TNFR: TNF receptor; Tregs: Regulatory T cells.

**Acknowledgements**
All figures were created with the assistance of Servier Medical Art (smart.server.com).

**Authors’ contributions**
XZ searched literatures. XY, LW searched literatures and prepared the original draft. JW and LH reviewed and edited the manuscript. All authors have agreed and read and agreed to the published version of the manuscript.

**Funding**
This work is supported by the fundings from the National Natural Science Foundation of China (81873427 and 82070217) to Dr. Jia Wei; 81900133 to Dr. Ling Ma; and CHEN XIAO-PING Foundation for the Development of Science and Technology of Hubei Province (QXJHJ2000009-113, to Dr. Jia Wei).

**Availability of data and materials**
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

**Declarations**

**Ethics approval and consent to participate**
Not applicable.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare no competing financial interests.

**Author details**
1 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 430030, Hubei, China. 1Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan 430030, Hubei, China. 2Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

**Received:** 31 October 2021 **Accepted:** 16 February 2022

**Published online:** 02 March 2022

**References**
1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.
2. Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13(1):72.
3. Menssen AJ, Walter MJ. Genetics of progression from MDS to secondary leukemia. Blood. 2020;136(1):50–60.
4. da Silva-Coelho P, Kroeze L, Yoshida K, Koorenhof-Scheele TN, Kröps R, van de Locht LT, et al. Clonal evolution in myelodysplastic syndromes. Nat Commun. 2017;8:15069.
5. Ghobrial IM, Detappe A, Anderson KC, Steensma DP. The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat Rev Clin Oncol. 2018;15(4):219–33.
6. Ogawa S. Genetics of MDS. Blood. 2019;133(10):1049–59.
7. Yu J, Li Y, Li T, Li Y, Xing H, Sun H, et al. Gene mutational analysis by NGS in MDS/AML patients. Exp Hematol Oncol. 2020;9:2.
8. Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383(14):1358–74.
9. Muto T, Walker CS, Choi K, Hueneman K, Smith MA, Gul Z, et al. Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. Nat Immunol. 2020;21(5):535–45.
10. Pallagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia. 2010;24(4):756–64.
11. Barenoy L, Chiot CN, Starczynowski DT. Chronic immune response dysregulation in MDS pathogenesis. Blood. 2018;132(15):1553–60.
12. Stomper J, Meier R, Ma T, Pfeifer D, Jhorst G, Blagiroko-Dorfs N, et al. Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients. Clin Epigenetics. 2021;13(1):77.
13. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, et al. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020;95(6):612–22.
14. Wei Y, Chen R, Dimicoli S, Bueso-Ramos C, Neuberg D, Pierce S, et al. Global H3K4me3 genome mapping reveals alterations of innate
immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia. 2013;27(11):2177–86.

15. Mallaney C, Ostrander EL, Celik H, Kramer AC, Martens A, Kothari A, et al. Kdm6b regulates context-dependent hematopoietic stem cell self-renewal and leukemogenesis. Leukemia. 2019;33(10):2506–21.

16. Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019;133(10):1039–48.

17. Basiora AA, McCraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016;128(25):2960–75.

18. Wang C, Yang Y, Gao S, Chen J, Yu J, Zhang H, et al. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies. Crit Rev Oncol Hematol. 2018;122:123–32.

19. Wang M, Zhang C, Tian T, Zhang T, Wang R, Fan F, et al. Increased regulatory T cells in peripheral blood of acute myeloid leukemia patients rely on tumor necrosis factor (TNF)-a-TNF receptor-2 pathway. Front Immunol. 2018;9:1274.

20. Ozkazanc D, Yoyen-Ermis D, Taukucuoglu E, Buyukasik Y, Esenbagl G. Functional exhaustion of CD4(+) T cells induced by co-stimulatory signals from myeloid leukemia cells. Immunology. 2016;149(4):460–71.

21. Epling-Burnette PK, Baker PJ, Rossion DL, Salih HR, Krusch M, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007;109(14):4816–24.

22. Liu G, Zhang Q, Yang J, Li X, Xian L, Li W, et al. Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis. Cancer Immunol Immunother. 2021;70(2):277–87.

23. Tan J, Chen S, Lu Y, Yao D, Xu L, Zhang Y, et al. Higher PD-1 expression concurrent with exhausted CD4+ T cells in patients with de novo acute myeloid leukemia. Chin J Cancer Res. 2017;29(5):463–70.

24. Shenghui Z, Yixiang H, Jianbo W, Kang Y, Laixi B, Yan Z, et al. Elevated frequencies of CD4+ CD25+ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer. 2011;129(6):1373–81.

25. Wan Y, Zhang C, Xu Y, Wang M, Rao Q, Xing H, et al. Hyperfunction of CD4 CD25 regulatory T cells in de novo acute myeloid leukemia. BMC Cancer. 2020;20(1):472.

26. Coats T, Smith A, Mourikis TP, Irish JM, Kordasti S, Mufti GJ. Mass cytometry reveals PD1 upregulation is an early step in MDS disease progression. Blood. 2016;128(22):4296.

27. Xu L, Liu L, Yao O, Zeng X, Zhang Y, Lai J, et al. PD-1 and TIGIT are highly co-expressed on CD4+ T cells in AML patient bone marrow. Front Oncol. 2021;11:686156.

28. Kikushige Y, Miyamoto T, Yuda J, Jabbarzadeh-Tabrizi S, Shima T, et al. Phenotypic and functional characteristics of tumor-infiltrating T cells in patients with acute myeloid leukemia. Chin J Cancer Res. 2017;29(5):463–70.

29. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and immune tolerance. Cell. 2008;133(5):775–87.

30. Meng F, Li L, Lu F, Yue J, Liu Z, Zhang W, et al. Overexpression of TIGIT in AML patient bone marrow. Front Immunol. 2020;11:686156.

31. Kondo A, Yamashita T, Tamura H, Zhao W, Tsuji T, Shimizu M, et al. Programmed death-1 signaling and regulatory T cells collaborate to resist the immune microenvironment in acute myeloid leukemia. Oncol Rep. 2020;43(3):999–1009.

32. Zhou Q, Munger ME, Veenastra RG, Weigel BJ, Hirashima M, Munn DH, et al. OX40L signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell Rep. 2017;20(8):2603–19.

33. Chang C-H, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(8):1229–41.

34. Chen C, Liang C, Wang J, Chen YL, Zeng C, et al. Expression patterns of immune checkpoints in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):28.

35. Meng F, Li L, Lu F, Yue J, Liu Z, Zhang W, et al. Overexpression of TIGIT in NK and T cells contributes to tumor immune escape in myelodysplastic syndromes. Front Oncol. 2020;10:15955.

36. Kondo A, Yamashita T, Tamura H, Zhao W, Tsuji T, Shimizu M, et al. Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7–H1, via nuclear factor-kappaB activation in myeloid leukaemia cells. Immunology. 2016;149(4):460–71.

37. Kuroiwa A, Yamauchi Y, Morita Y, Takeuchi H, et al. PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Oncol Rep. 2020;43(3):999–1009.

38. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab in patients with advanced renal cell carcinoma. N Engl J Med. 2015;372(4):320–30.

39. Beckman TK, de Maat MP, Boudreau LA, et al. Programmed death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced melanoma. Clin Cancer Res. 2014;20(17):4554–52.

40. Jono H, Oi H, Toike T, et al. PD-1 and PD-L1 expression drives glycolysis via an Akt/mTOR/HIF-1α axis in acute myeloid leukemia. Oncol Rep. 2020;43(3):999–1009.

41. Jokula A, Kuntz D, Schickel D, et al. PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol Cell Biol. 2013;33(16):3091–8.
61. Chen Y, Wang Y, Luo H, Meng X, Zhu W, Wang D, et al. The frequency
62. Cheng P, Eksioglu EA, Chen X, Kandell W, Le Trinh T, Cen L, et al.
64. Dolen Y, Esendagli G. Myeloid leukemia cells with a B7–2(
67. Tcvetkov NY, Morozova EV, Epifanovskaya OS, Babenko EV, Barabanshi-
70. Moskorz W, Cosmovici C, Jäger PS, Cadeddu RP, Timm J, Haas R. Myelo-
71. Brodská B, Otevřelová P, Šálek C, Fuchs O, Gašová Z, Kuželová K. High
72. Tamura H, Dan K, Tamada K, Nakamura K, Shioi Y, Hyodo H, et al.
73. Zhang ZF, Zhang QT, Xin HZ, Gan SL, Ma J, Liu YF, et al. Expression
74. Krönig H, Kremmler L, Haller B, Englert C, Peschel C, Andreesen R, et al.
78. Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Ning J, et al.
79. Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz J,
80. Sallman DA, McMenemy AF, Aldrich AL, Komorjki RS, McGraw KL, 
81. Zeidan AM, Bewersdorf JPP, Hasle V, Thompson EG, Lopes de 
82. Nazha A. The MDS genomics-prognosis symbiosis. Hematol Am Soc 
87. Fang X, Chen C, Xia F, Yu Z, Zhang Y, Zhang F, et al. CD274 promotes cell
88. Fisher DAC, Fowles JS, Zhou A, Oh ST. Inflammatory pathophysiology
90. Fisher DAC, Fowles JS, Zhou A, Oh ST. Inflammatory pathophysiology
91. Binder S, Luciano M, Horejs-Hoeck J. The cytokine network in acute
92. Ciciarello M, Corradi G, Sangaletti S, Bassani B, Simonetti G, Vadake-
97. Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, et al.
98. Gersuk-GM, Beckham C, Loken MR, Kieener P, Anderson JE, Farrand A, 
99. Mundle SD, Reza S, Ali A, Mativi Y, Shetty V, Venugopal P, et al. Correlation of tumor necrosis factor alpha (TNF alpha) with high 
100. Shi L, Zhao Y, Fei C, Guo J, Jia Y, Wu D, et al. Cellular senescence induced by 
101. Hossain DM, Dos Santos C, Zhang Q, Kozloska A, Liu H, Gao C, et al. 
102. Page 19 of 21
99. Moshofsky KB, Cho HJ, Wu G, Rominae KA, Newman MT, Kosaka Y, et al. Acute myeloid leukemia-induced T-cell suppression can be reversed by inhibition of the MAPK pathway. Blood Adv. 2019;3(20):3038–41.

100. Yi M, Xu L, Jiao Y, Luo S, Li A, Wu K. The role of cancer-derived microRNAs in cancer immune escape. J Hematol Oncol. 2020;13(1):25.

101. Pyzer AR, Stroopinsky D, Rosenblatt J, Anastassiadou E, Rajabi H, Washington A, et al. MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia. 2017;31(12):2780–90.

102. Youngblood B, Oestreich KJ, Ha SJ, Duraiswamy J, Akondy RS, West EE, et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity. 2013;35(3):400–12.

103. Lindblad KE, Goswami M, Hourigan CS, Oetjen KA. Immuno- logical effects of hypomethylating agents. Expert Rev Hematol. 2017;10(8):745–52.

104. Herbrich S, Baran N, Cai T, Weng C, Atken ML, Post SM, et al. Over-expression of CD200 is a stem cell-specific mechanism of immune evasion in AML. J Immunother Cancer. 2021;9(7):e002968.

105. Coles SJ, Wang EC, Man S, Hills RK, Burnett AK, Tonks A, et al. CD200 expression supresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia. 2011;25(5):792–9.

106. Coles SJ, Gilmour MN, Reid R, Knapper S, Burnett AK, Man S, et al. The immunosuppressive ligands PD-1 and CD200 are linked in AML, T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia. 2015;29(9):1918.

107. Santini V. How I treat MDS after hypomethylating agent failure. Blood. 2019;133(6):521–9.

108. Pribet T, Gore SD, Estern B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3222–7.

109. Jabbour E, Garcia-Manero G, Batty N, Shan J, O’Brien S, Cortes J, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116(16):3830–4.

110. Umnikrishnan A, Papaemmanuili E, Beek D, Deshpande NP, Verma A, Kumar A, et al. Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes. Cell Rep. 2017;20(3):572–85.

111. Qin T, Castoro R, El Ahdab S, Jelinek J, Wang X, Si J, et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS ONE. 2011;6(8):e23372.

112. Vidal V, Robert G, Gourraud L, Durand L, Ginet C, Karsenti JM, et al. BCL2L10 positive cells in bone marrow are an independent prognostic factor for azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. Oncotarget. 2017;8(29):47103–9.

113. Zeidan AM, Cavenagh J, Voso MT, Tassig D, Tormo M, Ross E, et al. Efficacy and safety of azacitidine in combination with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021;195(3):378–97.

114. Chien KS, Borthakur G, Ribeiro RC, Daver N, Montalban-Braudo G, Daver NG, et al. Final results from a phase II study combining azacitidine and pembrolizumab in patients with higher-risk myelodysplastic syndrome after failure of hypomethylating agent therapy. Blood. 2020;136(1):132–3.

115. Zeidman AM, Cavenagh J, Voso MT, Tassig D, Tormo M, Ross E, et al. Efficacy and safety of azacitidine (AZA) in combination with pembrolizumab (pembrolizumab) for the front-line treatment of older patients (pts) with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy (IC) and who have a high-risk myelodysplastic syndrome (HR-MDS): results from a large, international, randomized phase 2 study. Blood. 2019;134(Supplement_1):829.

116. Vereereque R, Saudemont A, Quenuel B. Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia. 2004;18(7):1223–30.

117. Zeidman AM, Cavenagh J, Voso MT, Tassig D, Tormo M, Ross E, et al. Efficacy and safety of azacitidine (AZA) in combination with pembrolizumab (pembrolizumab) for the front-line treatment of older patients (pts) with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy (IC) and who have a high-risk myelodysplastic syndrome (HR-MDS): results from a large, international, randomized phase 2 study. Blood. 2019;134(Supplement_1):829.
138. Assi R, Kantarjian HM, Daver NG, Garcia-Manero G, Bentley CB, Thompson PA, et al. Results of a phase 2, open-label study of idarubicin (I), cytarabine (A) and nivolumab (Nivo) in patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2018;132(Supplement 1):905.

139. Chien KS, Borthakur G, Naqvi K, Daver N, Montalban Bravo G, Cortes JE, et al. Updated results from a phase II study combining azacitidine and per-brolizumab in previously-untreated patients with higher-risk myelodysplastic syndrome. Blood. 2020;136(Supplement 1):38–9.

140. Bacher U, Shumilov E, Flach J, Porret N, Joncourt R, Wiedemann G, et al. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. Blood Cancer J. 2018;8(11):113.

141. Spaulding TP, Stockton SS, Savona MR. The evolving role of next-generation sequencing in myelodysplastic syndromes. Br J Haematol. 2020;188(2):224–39.

142. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. A precision medicine classification for treatment of acute myeloid leukemia in older patients. Hematol Oncol. 2019;37(1):1–22.

143. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Publisher’s Note

144. Yagi T, Baba Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, et al. PD-L1 expression, tumor-infiltrating lymphocytes, and clinical outcome in patients with surgically resected esophageal cancer. Ann Surg. 2019;269(3):471–8.

145. Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 programmed cell death ligand 1 as a novel biomarker for nivolumab therapy in non-small-cell lung cancer. Clin Lung Cancer. 2018;19(5):410–417.e1.

146. Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 2018;29(1):71–83.

147. Qin S, Xu Y, Li Y, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:219(1):135.

148. Liu L, Chang YJ, Xu LP, Zhang XH, Wang Y, Liu KY, et al. Reversal of T cell exhaustion by the first donor lymphocyte infusion is associated with the persistently effective antileukemic responses in patients with relapsed AML after Allo-HSCT. Biol Blood Marrow Transplant. 2018;24(7):1550–9.

149. Noviello M, Manfredi F, Ruggiero E, Perini T, Oliveira G, Cortesi F, et al. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat Commun. 2019;10(1):1065.

150. Liu S, Zhang T, Zheng L, Liu H, Song W, Liu D, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14(1):155.

151. Wei AH, Esteve J, Porkka K, Knapper S, Vey N, Scholl S, et al. Elevated TIM3 expression of T helper cells affects immune system in patients with myelodysplastic syndrome. J Invest Med. 2016;68(1):1125–30.

152. Yi M, Zhang X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/ PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.

153. Asayama T, Tamura H, Ishibashi M, Kunitabayashi-Hamada Y, Onodera-Kondo A, Okuyama N, et al. Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes. Oncotarget. 2017;8(5):8904–17.

154. Tao J, Li L, Fu R, Wang HQ, Jiang HJ, Yue LZ, et al. Elevated TIM3+ hematopoietic stem cells in untreated myelodysplastic syndrome displayed aberrant differentiation, overproliferation and decreased apoptosis. Leuk Res. 2014;38(6):714–21.

155. Ostendorf BN, Flener E, Florcken A, Westermann J. Phenotypic characterization of aberrant stem and progenitor cell populations in myelodysplastic syndromes. PLoS ONE. 2018;13(5):e0197823.

156. Wang PW, Pluvinage JV, Price EA, Sridhar K, Arber DA, Greenberg PL, et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci USA. 2013;110(8):3011–6.

157. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286–99.

158. Monta K, Kantarjian HM, Montalban Bravo G, Sasaki K, Daver N, Jabbour E, et al. A phase II study of double immune checkpoint inhibitor blockade with nivolumab and ipilimumab with or without azacitidine in patients with myelodysplastic syndrome (MDS). Blood. 2020;136(Supplement 1):7–9.

159. Wei AH, Esteve J, Porrka K, Knapper S, Vey N, Scholl S, et al. SaliBamlomab (MBG63) dose selection and dose-response analysis in myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML): population pharmacokinetics (PK) modeling and evaluation of clinical efficacy/safety by dose. Blood. 2020;136(Supplement 1):40–2.

160. Takeda S, Vick B, Hiller B, Schmitz S, Marcinek A, Perini ED, et al. SIRPa-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearence of AML-initiating cells. J Hematol Oncol. 2021;14(1):135.

161. Finkelman DA, Asch AS, Al-Malki MM, Lee DJ, Donnellan WB, Maruccio G, et al. The first-in-class anti-CD47 antibody magrolimab (SF94) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results. Blood. 2019;134(Supplement 1):569.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.